Clinical trials: Schizophrenia
Schizophrenia
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
This is an efficacy study evaluating a experimental treatment for cognitive deficits in adults with schizophrenia.
- Trial name
- NCT01678755
- Testing
- ABT-126
- Where
- 20 sites in United States
- Volunteers
- 157 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Schizophrenia
Safety, Tolerability, Pharmacokinetics and Efficacy Study of HS-10380 in Patients With Schizophrenia
The objective of this study is to evaluate the safety, tolerability, pharmacokinetics and efficacy of HS-10380 relative to placebo for the treatment of participants with schizophrenia.
- Trial name
- NCT05964790
- Testing
- HS-10380
- Volunteers
- 112 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Schizophrenia
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
The purpose of this study is to determine whether LY2140023, when added to standard-of-care antipsychotic treatment, will improve negative symptoms.
- Trial name
- NCT01052103
- Testing
- LY2140023, Standard of Care
- Where
- 9 sites in United States, Israel and 2 more
- Volunteers
- 167 people
- Sponsor
- Denovo Biopharma LLC
Schizophrenia
PK Study of Aripiprazole IM Depot for Chinese Patients With Schizophrenia
This study assess pharmacokinetics and safety of multi-administration of Aripiprazole IM Depot formulation at doses of 400mg in patients with schizophrenia.
- Trial name
- NCT03285503
- Testing
- Aripiprazole IM Depot
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Otsuka Beijing Research Institute
Schizophrenia, Autism
Pediatric Open-Label Extension Study
This is an open-label, 104-week, multicenter, extension study designed to evaluate the long-term safety, tolerability and effectiveness of flexibly dosed lurasidone (20, 40, 60 or 80 mg/day) in pediatric subjects who have…
- Conditions
- Schizophrenia, Autism, Bipolar Depression
- Trial name
- NCT01914393
- Testing
- Lurasidone 20, 40, 60, 80 mg, flexibly dosed
- Where
- 88 sites in United States, Bulgaria and 13 more
- Volunteers
- 702 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study…
- Trial name
- NCT07459647
- Testing
- ML-007C-MA
- Where
- 45 sites in United States
- Volunteers
- 500 people
- Sponsor
- MapLight Therapeutics
Schizophrenia
Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia
Lurasidone HCl is a compound developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is more efficacious than placebo.
- Trial name
- NCT00615433
- Testing
- Lurasidone, Olanzapine, Lurasidone 40 mg tablets
- Where
- 52 sites in United States, Colombia and 3 more
- Volunteers
- 478 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia
A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia
To evaluate the safety and tolerability of multiple doses of PF 02545920 administered orally to psychiatrically stable subjects with schizophrenia receiving background antipsychotic +/- other adjunctive medication.
- Trial name
- NCT01829048
- Testing
- PF-02545920
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Pfizer
Schizophrenia, Bipolar I Disorder
A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder
The purpose of this trial is to determine the safety and tolerability of multiple-dose administrations of aripiprazole, to establish the similarity of aripiprazole concentrations on the last day of the dosing interval following…
- Trial name
- NCT04030143
- Testing
- Aripiprazole
- Where
- 19 sites in United States
- Volunteers
- 266 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Effect on Cognitive Function of a Treatment With Aripiprazole
To evaluate the effectiveness of Aripiprazole after 12 weeks of therapy for Schizophrenic patients.
- Trial name
- NCT00329810
- Testing
- Aripiprazole
- Volunteers
- 500 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Pharmacokinetic Study of the Relative Bioavailability of Paliperidone ER Formulations With Different Release Profiles and a Comparison to Paliperidone IR
The primary purpose of this study is to evaluate the pharmacokinetics and relative bioavailability of paliperidone ER formulations with slow, target, and fast in vitro release rates after administration of a single 12 mg dose.
- Trial name
- NCT00791193
- Testing
- Paliperidone ER
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
The purpose of the protocol is to evaluate the efficacy of olanzapine compared with Aripiprazole in patients with schizophrenia.
- Trial name
- NCT00088049
- Testing
- Olanzapine, Aripiprazole
- Where
- 24 sites in United States
- Volunteers
- 560 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years
The study will assess the use of paliperidone palmitate compared with oral risperidone in delaying time to relapse in patients recently diagnosed with schizophrenia who are at high risk of relapse.
- Trial name
- NCT00946985
- Testing
- paliperidone palmitate, oral risperidone
- Where
- 72 sites in United States, Brazil and 10 more
- Volunteers
- 163 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Schizophrenia
Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia
This study will evaluate the effects of sequential multiple dose regimens of cariprazine on cardiac repolarization in patients with schizophrenia.
- Trial name
- NCT01376076
- Testing
- Cariprazine, Risperidone/Moxifloxacin
- Where
- 4 sites in United States
- Volunteers
- 129 people
- Sponsor
- Forest Laboratories
Schizophrenia
Safety Study of an Antipsychotic, Sertindole, to Treat Schizophrenia
The purpose of this study is to permit the patients with schizophrenia who received Sertindole during a previous randomised trial, study 99824, to continue with this treatment.
- Trial name
- NCT00763438
- Testing
- Sertindole
- Where
- France
- Volunteers
- 18 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
A Phase 4 Study to Evaluate Response to Treatment and Safety of Paliperidone Extended-Release in Participants With Schizophrenia
The purpose of this study is to evaluate the response to treatment and safety of paliperidone extended-release (mechanism to dissolve a drug over time in order to be released slower and steadier into the blood stream) in…
- Trial name
- NCT00915512
- Testing
- Paliperidone extended-release (ER)
- Where
- 7 sites in Turkey (Türkiye)
- Volunteers
- 84 people
- Sponsor
- Janssen-Cilag Turkey
Schizophrenia
Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia
This will be a multicenter, randomized, double-blind, placebo-controlled study designed to assess the tolerability, safety, and efficacy of OPC-34712 (0.25 to 6.0 mg) for the treatment of adult subjects hospitalized with an acute…
- Trial name
- STEP 203 (NCT00905307)
- Testing
- OPC-34712, Aripiprazole
- Where
- 73 sites in United States, Bulgaria and 10 more
- Volunteers
- 459 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Trial Evaluating Three Fixed Dosages of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia
The primary objective of the double blind phase of this study is to evaluate the efficacy and safety of 3 fixed dosages of paliperidone ER (6, 9, and 12 mg/day) compared with placebo in adult patients with schizophrenia.
- Trial name
- NCT00078039
- Testing
- Paliperidone ER
- Volunteers
- 630 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizoaffective Disorder
A Safety and Pharmacokinetic Study of ER OROS Paliperidone in Pediatric Patients With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder
The purposes of this study are to characterize the pharmacokinetics of paliperidone after single- and multiple-dose administration of paliperidone ER in children and adolescent patients (>= 10 to <= 17 years of age) with…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
- Trial name
- NCT00796081
- Testing
- ER OROS paliperidone, paliperidone ER
- Volunteers
- 25 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release Formulations
The purpose of this study is to evaluate the pharmacokinetics of 2 extended-release (ER) formulations of 2 mg-eq paliperidone in comparison to the 2 mg immediate-release (IR) paliperidone oral solution and to evaluate the effect…
- Trial name
- NCT00796471
- Testing
- Paliperidone ER
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.